Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.56 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.49 |
| ▸ | ITGAV | P06756 | 6/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.45 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162595 | 0.81 | LMNA (0.63) | FFAR1PPARGCYP3A4RXRAL3MBTL1 | |
| SCHEMBL5803612 | 0.81 | PPARG (0.52) | FFAR1PPARGCYP3A4RXRAITGB3 | |
| SCHEMBL5803154 | 0.80 | PPARG (0.52) | FFAR1PPARGCYP3A4RXRAL3MBTL1 | |
| SCHEMBL943063 | 0.79 | PPARG (0.58) | PPARGCYP3A4RXRAPOLB | |
| SCHEMBL1201520 | 0.79 | PPARG (0.51) | FFAR1PPARGCYP3A4RXRAITGB3 | |
| SCHEMBL1199905 | 0.79 | PPARG (0.51) | FFAR1PPARGCYP3A4RXRAITGB3 | |
| SCHEMBL5804522 | 0.79 | PPARG (0.51) | FFAR1PPARGCYP3A4RXRAITGB3 | |
| SCHEMBL5822018 | 0.78 | PPARG (0.54) | FFAR1PPARGCYP3A4RXRAL3MBTL1 | |
| SCHEMBL5802960 | 0.77 | PPARG (0.51) | PPARGCYP3A4RXRAITGB3ITGAV | |
| SCHEMBL3313236 | 0.77 | PPARG (0.58) | FFAR1PPARGCYP3A4RXRAITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663170-B1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ANDRX LABS LLC (US) | 2015-06-24 | — | — | EP | claimed |
| US-9060941-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. (US) | 2015-06-23 | — | — | US | claimed |
| US-8668931-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-20130266647-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ACTAVIS HOLDCO US, INC. | 2013-10-10 | — | — | US | claimed |
| US-8470368-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | WATSON PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-20110262538-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | WATSON PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| US-7959946-B2 | Sustained release; hypoglycemic agents; synergistic mixture | WATSON PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| EP-1863445-B1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | WATSON PHARMACEUTICALS INC (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-1663170-B1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ANDRX LABS LLC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-9060941-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150072001-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | WATSON PHARMACEUTICALS INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8668931-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130266647-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ACTAVIS HOLDCO US, INC. | 2013-10-10 | — | — | US | disclosed |
| EP-1863445-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | Watson Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006107528-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | WATSON PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1663170-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | Andrx Labs Llc (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050249809-A1 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | WATSON PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050226928-A1 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2005039540-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ANDRX LABS LLC (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040161462-A1 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS HOLDCO US, INC. | 2004-08-19 | — | — | US | disclosed |